UA76398C2 - Solid compositions containing gamma-aminobutyric acid derivative and method for their manufacture - Google Patents

Solid compositions containing gamma-aminobutyric acid derivative and method for their manufacture Download PDF

Info

Publication number: UA76398C2
Authority: UA; Ukraine
Prior art keywords: group; substituted; amino; gabapentin; carbon atoms
Prior art date: 1998-05-15

Application number

UA2000127205A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-15

Filing date

1999-10-05

Publication date

2006-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA76398(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-05-10 Priority claimed from PCT/US1999/010186 external-priority patent/WO1999059572A1/en

1999-10-05 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2006-08-15 Publication of UA76398C2 publication Critical patent/UA76398C2/uk

Links

239000008247 solid mixture Substances 0.000 title abstract description 9
238000000034 method Methods 0.000 title description 25
238000004519 manufacturing process Methods 0.000 title description 21
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title description 3
-1 4-amino-3-substituted-butanoic acid Chemical class 0.000 abstract description 25
239000003906 humectant Substances 0.000 abstract description 11
239000003381 stabilizer Substances 0.000 abstract description 11
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 133
239000000843 powder Substances 0.000 description 68
229960002870 gabapentin Drugs 0.000 description 66
125000004432 carbon atom Chemical group C* 0.000 description 49
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 36
125000000217 alkyl group Chemical group 0.000 description 33
239000003826 tablet Substances 0.000 description 31
238000002360 preparation method Methods 0.000 description 28
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 27
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 27
239000002775 capsule Substances 0.000 description 22
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 22
125000003277 amino group Chemical group 0.000 description 21
125000005843 halogen group Chemical group 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
239000008187 granular material Substances 0.000 description 20
125000002887 hydroxy group Chemical group [H]O* 0.000 description 20
239000000203 mixture Substances 0.000 description 20
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 20
229960001233 pregabalin Drugs 0.000 description 20
229940079593 drug Drugs 0.000 description 19
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 19
239000003814 drug Substances 0.000 description 18
125000003545 alkoxy group Chemical group 0.000 description 17
238000005469 granulation Methods 0.000 description 17
230000003179 granulation Effects 0.000 description 17
239000004474 valine Substances 0.000 description 16
239000002253 acid Substances 0.000 description 15
229960000310 isoleucine Drugs 0.000 description 15
239000000825 pharmaceutical preparation Substances 0.000 description 15
239000007787 solid Substances 0.000 description 15
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 15
150000004648 butanoic acid derivatives Chemical class 0.000 description 14
150000004652 butanoic acids Chemical class 0.000 description 14
125000000753 cycloalkyl group Chemical group 0.000 description 14
239000000243 solution Substances 0.000 description 14
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
229960000794 baclofen Drugs 0.000 description 13
230000015556 catabolic process Effects 0.000 description 13
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 12
125000004414 alkyl thio group Chemical group 0.000 description 12
239000011248 coating agent Substances 0.000 description 12
238000000576 coating method Methods 0.000 description 12
238000006731 degradation reaction Methods 0.000 description 12
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 11
150000003951 lactams Chemical group 0.000 description 11
125000004043 oxo group Chemical group O=* 0.000 description 11
239000000126 substance Substances 0.000 description 10
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 10
229940024606 amino acid Drugs 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
125000004429 atom Chemical group 0.000 description 9
238000006297 dehydration reaction Methods 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
125000002947 alkylene group Chemical group 0.000 description 8
238000003825 pressing Methods 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
125000000392 cycloalkenyl group Chemical group 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
230000004927 fusion Effects 0.000 description 7
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
230000007935 neutral effect Effects 0.000 description 7
125000001424 substituent group Chemical group 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
238000005755 formation reaction Methods 0.000 description 6
239000001863 hydroxypropyl cellulose Substances 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
239000004570 mortar (masonry) Substances 0.000 description 6
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
239000004909 Moisturizer Substances 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000018044 dehydration Effects 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 5
239000001087 glyceryl triacetate Substances 0.000 description 5
235000013773 glyceryl triacetate Nutrition 0.000 description 5
230000001333 moisturizer Effects 0.000 description 5
239000000600 sorbitol Substances 0.000 description 5
235000010356 sorbitol Nutrition 0.000 description 5
229960002622 triacetin Drugs 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
125000005119 alkyl cycloalkyl group Chemical group 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
235000019658 bitter taste Nutrition 0.000 description 4
238000009833 condensation Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
230000006641 stabilisation Effects 0.000 description 4
238000011105 stabilization Methods 0.000 description 4
208000018152 Cerebral disease Diseases 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
150000001875 compounds Chemical group 0.000 description 3
230000005494 condensation Effects 0.000 description 3
206010015037 epilepsy Diseases 0.000 description 3
238000005243 fluidization Methods 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000004321 preservation Methods 0.000 description 3
239000013589 supplement Substances 0.000 description 3
PWSUQCRPENFXDF-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-2-one Chemical compound C1NC(=O)CC1C1CCCCC1 PWSUQCRPENFXDF-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
244000269722 Thea sinensis Species 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000005037 alkyl phenyl group Chemical group 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000005056 compaction Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
150000002314 glycerols Chemical class 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000002574 poison Substances 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
FFLUTBMPHJSPSA-UHFFFAOYSA-N 2-(aminomethyl)-4-cyclohexylbutanoic acid Chemical compound NCC(C(O)=O)CCC1CCCCC1 FFLUTBMPHJSPSA-UHFFFAOYSA-N 0.000 description 1
QMSAQHYISIINGO-UHFFFAOYSA-N 2-(aminomethyl)-4-phenylbutanoic acid Chemical compound NCC(C(O)=O)CCC1=CC=CC=C1 QMSAQHYISIINGO-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
SMWZNXFMLNNMFB-UHFFFAOYSA-N 3-(aminomethyl)-4-phenylbutanoic acid Chemical compound OC(=O)CC(CN)CC1=CC=CC=C1 SMWZNXFMLNNMFB-UHFFFAOYSA-N 0.000 description 1
XZPXJXLIGDOBPD-UHFFFAOYSA-N 3-(aminomethyl)-5-phenylpentanoic acid Chemical compound OC(=O)CC(CN)CCC1=CC=CC=C1 XZPXJXLIGDOBPD-UHFFFAOYSA-N 0.000 description 1
AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical class COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
235000003097 Artemisia absinthium Nutrition 0.000 description 1
240000001851 Artemisia dracunculus Species 0.000 description 1
235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
235000003261 Artemisia vulgaris Nutrition 0.000 description 1
241000543381 Cliftonia monophylla Species 0.000 description 1
244000157795 Cordia myxa Species 0.000 description 1
235000004257 Cordia myxa Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
244000241257 Cucumis melo Species 0.000 description 1
235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
241000514450 Podocarpus latifolius Species 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
235000011449 Rosa Nutrition 0.000 description 1
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
240000005481 Salvia hispanica Species 0.000 description 1
235000001498 Salvia hispanica Nutrition 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
241001648319 Toronia toru Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001356 alkyl thiols Chemical class 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
239000001138 artemisia absinthium Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000001273 butane Substances 0.000 description 1
WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
235000014167 chia Nutrition 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
238000007373 indentation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
PZYDAVFRVJXFHS-UHFFFAOYSA-N n-cyclohexyl-2-pyrrolidone Chemical compound O=C1CCCN1C1CCCCC1 PZYDAVFRVJXFHS-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
239000003973 paint Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
108090000623 proteins and genes Chemical group 0.000 description 1
239000011435 rock Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
235000014101 wine Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Arrangement Of Transmissions (AREA)
Body Structure For Vehicles (AREA)

UA2000127205A 1998-05-15 1999-10-05 Solid compositions containing gamma-aminobutyric acid derivative and method for their manufacture UA76398C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP13312298A JP3761324B2 (ja)	1998-05-15	1998-05-15	乗用田植機
PCT/US1999/010186 WO1999059572A1 (en)	1998-05-15	1999-05-10	Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same

Publications (1)

Publication Number	Publication Date
UA76398C2 true UA76398C2 (en)	2006-08-15

Family

ID=15097314

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000127205A UA76398C2 (en)	1998-05-15	1999-10-05	Solid compositions containing gamma-aminobutyric acid derivative and method for their manufacture

Country Status (16)

Country	Link
JP (1)	JP3761324B2 (de)
CN (1)	CN1171587C (de)
AT (1)	ATE407668T1 (de)
CA (1)	CA2325045C (de)
CY (1)	CY1108488T1 (de)
DE (1)	DE69939532D1 (de)
DK (1)	DK1077691T3 (de)
EA (1)	EA006553B1 (de)
EE (1)	EE05530B1 (de)
EG (1)	EG26287A (de)
ES (1)	ES2312208T3 (de)
GE (1)	GEP20032987B (de)
IL (2)	IL139202A0 (de)
NZ (1)	NZ507162A (de)
PT (1)	PT1077691E (de)
UA (1)	UA76398C2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4904636B2 (ja) *	2001-05-29	2012-03-28	井関農機株式会社	トラクタフレーム
JP5047022B2 (ja) *	2008-03-24	2012-10-10	ヤンマー株式会社	上下分割式のエンジン収納用パッケージの結合構造
WO2013008182A1 (en) *	2011-07-10	2013-01-17	Mahesh Kandula	Prodrugs of gaba analogs
US9303038B2 (en)	2011-09-06	2016-04-05	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168019A1 (en) *	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neuropathic pain
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167985A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of depression
US9403826B2 (en)	2012-05-08	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en)	2012-05-08	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of parkinson's disease
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
WO2013168010A1 (en) *	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of severe pain
WO2013168033A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neurologic diseases
WO2013168014A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168012A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en)	2012-05-10	2016-01-12	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological conditions
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
US9403857B2 (en)	2012-05-10	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2013168000A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of severe pain
US9394288B2 (en)	2012-05-10	2016-07-19	Cellix Bio Private Limited	Compositions and methods for the treatment of asthma and allergy
US9273061B2 (en)	2012-05-10	2016-03-01	Cellix Bio Private Limited	Compositions and methods for the treatment of chronic pain
WO2013168005A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9227974B2 (en)	2012-05-23	2016-01-05	Cellex Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en)	2012-05-23	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of mucositis
EP2852569B1 (de)	2012-05-23	2020-10-14	Cellixbio Private Limited	Zusammensetzungen und verfahren zur behandlung von multipler sklerose
US9492409B2 (en)	2012-05-23	2016-11-15	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
WO2013175344A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en)	2012-05-23	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh)	2012-09-08	2015-02-18	塞利克斯比奥私人有限公司	用于治疗炎症和脂质异常的组合物和方法
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (de)	2013-06-04	2018-09-05	Cellixbio Private Limited	Zusammensetzungen und verfahren zur behandlung von diabetes und prädiabetes
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
EP3240779B1 (de)	2014-09-26	2020-10-28	Cellixbio Private Limited	Zusammensetzungen und verfahren zur behandlung von epilepsie- und lipidstörungen
JP6698643B2 (ja)	2014-09-29	2020-05-27	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	多発性硬化症の治療のための組成物及び方法
CN104352476A (zh) *	2014-10-21	2015-02-18	齐宏	一种加巴喷丁胶囊及其制备方法
AU2014414316B2 (en)	2014-10-27	2020-04-09	Cellix Bio Private Limited	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en)	2014-12-01	2018-04-03	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
CA2973178C (en)	2015-01-06	2022-11-01	Cellix Bio Private Limited	Bupivacaine derivatives and their use in the treatment of inflammation and pain

1998
- 1998-05-15 JP JP13312298A patent/JP3761324B2/ja not_active Expired - Fee Related
1999
- 1999-05-10 PT PT99924164T patent/PT1077691E/pt unknown
- 1999-05-10 EA EA200001154A patent/EA006553B1/ru not_active IP Right Cessation
- 1999-05-10 CA CA002325045A patent/CA2325045C/en not_active Expired - Lifetime
- 1999-05-10 IL IL13920299A patent/IL139202A0/xx unknown
- 1999-05-10 ES ES99924164T patent/ES2312208T3/es not_active Expired - Lifetime
- 1999-05-10 DE DE69939532T patent/DE69939532D1/de not_active Expired - Lifetime
- 1999-05-10 CN CNB998059781A patent/CN1171587C/zh not_active Expired - Fee Related
- 1999-05-10 DK DK99924164T patent/DK1077691T3/da active
- 1999-05-10 EE EEP200000671A patent/EE05530B1/xx unknown
- 1999-05-10 GE GEAP19995678A patent/GEP20032987B/en unknown
- 1999-05-10 NZ NZ507162A patent/NZ507162A/en not_active IP Right Cessation
- 1999-05-10 AT AT99924164T patent/ATE407668T1/de active
- 1999-05-13 EG EG1999050553A patent/EG26287A/en active
- 1999-10-05 UA UA2000127205A patent/UA76398C2/uk unknown
2000
- 2000-10-23 IL IL139202A patent/IL139202A/en not_active IP Right Cessation
2008
- 2008-11-06 CY CY20081101268T patent/CY1108488T1/el unknown

Also Published As

Publication number	Publication date
EA200001154A1 (ru)	2001-06-25
EA006553B1 (ru)	2006-02-24
IL139202A (en)	2014-12-31
GEP20032987B (en)	2003-06-25
JP3761324B2 (ja)	2006-03-29
PT1077691E (pt)	2008-11-04
CY1108488T1 (el)	2014-04-09
DE69939532D1 (de)	2008-10-23
EE200000671A (et)	2002-04-15
CN1300213A (zh)	2001-06-20
NZ507162A (en)	2003-11-28
CN1171587C (zh)	2004-10-20
ES2312208T3 (es)	2009-02-16
EG26287A (en)	2013-06-12
DK1077691T3 (da)	2008-10-27
EE05530B1 (et)	2012-04-16
JPH11318133A (ja)	1999-11-24
CA2325045A1 (en)	1999-11-25
CA2325045C (en)	2005-05-03
ATE407668T1 (de)	2008-09-15
IL139202A0 (en)	2001-11-25

Publication	Publication Date	Title
UA76398C2 (en)	2006-08-15	Solid compositions containing gamma-aminobutyric acid derivative and method for their manufacture
JP3527729B2 (ja)	2004-05-17	４−アミノ−３−置換−ブタン酸誘導体含有固形組成物およびその製造法
JP5406049B2 (ja)	2014-02-05	グルタチオンの保存安定性向上方法
CN104173272B (zh)	2021-07-06	一种异硫氰酸酯类化合物的缓释制剂
PL204921B1 (pl)	2010-02-26	Stabilizowana kompozycja farmaceutyczna zawierająca 4-amino-3-podstawioną pochodną kwasu butanowego i α-aminokwas oraz sposób jej wytwarzania
WO2003041700A1 (en)	2003-05-22	Storage stable thyroxine active drug formulations
HUE030788T2 (en)	2017-06-28	Oral dosage form containing lacarbazepine acetate
JP2003509373A (ja)	2003-03-11	固体脂質処方
EA027721B1 (ru)	2017-08-31	Препараты, содержащие 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диол
JPH06502148A (ja)	1994-03-10	抗うつ剤
WO2003041699A1 (en)	2003-05-22	Storage stable thyroxine active drug formulations and methods for their production
DE2211019B2 (de)	1979-12-20	Geschmacksverbessernde Formulierungen oraler Penicilline
CA2703224A1 (en)	2009-04-30	Pharmaceutical formulation of clavulanic acid
EP2661252A1 (de)	2013-11-13	Wasserlösliche dosierformen
KR100281521B1 (ko)	2001-02-15	프라바스타틴나트륨이 함유된 약제 조성물
WO2007128495A2 (en)	2007-11-15	Solid pharmaceutical composition of gabapentin
US20150072014A1 (en)	2015-03-12	Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid
CA2035841C (en)	1996-02-13	Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture
ES2770500T3 (es)	2020-07-01	Composición farmacéutica que comprende fingolimod
KR102758107B1 (ko)	2025-01-20	페오놀 및 아포시닌을 포함하는 액체 제형
JPH07118148A (ja)	1995-05-09	肝癌予防剤
KR20010057545A (ko)	2001-07-04	프라지콴텔을 포함하는 서방성 구충제 조성물
KR101175120B1 (ko)	2012-08-21	나테글리니드 함유 제제
US20230051579A1 (en)	2023-02-16	Process for preparing cannabinoid-containing particles
RU2174836C1 (ru)	2001-10-20	Фармацевтическая композиция, обладающая анальгезирующим действием